Management of biochemical recurrence after primary treatment of prostate cancer: A systematic review of the literature

Sanoj Punnen, Matthew R. Cooperberg, Anthony V. D'Amico, Pierre I. Karakiewicz, Judd W. Moul, Howard I. Scher, Thorsten Schlomm, Stephen J. Freedland

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Context Despite excellent cancer control with the treatment of localized prostate cancer (PCa), some men will experience a recurrence of disease. The optimal management of recurrent disease remains uncertain. Objective To systematically review recent literature regarding management of biochemical recurrence after primary treatment for localized PCa. Evidence acquisition A comprehensive systematic review of the literature was performed from 2000 to 2012 to identify articles pertaining to management after recurrent PCa. Search terms included prostate cancer recurrence, salvage therapy, radiorecurrent prostate cancer, post HIFU, post cryoablation, postradiation, and postprostatectomy salvage. Studies were selected according to Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines and required to provide a comprehensive description of primary and secondary treatments along with outcomes. Evidence synthesis The data from 32 original publications were reviewed. The most common option for local salvage therapy after radical prostatectomy (RP) was radiation. Options for local salvage therapy after primary radiation included RP, brachytherapy, and cryotherapy. Different definitions of recurrence and risk profiles among patients make comparative assessment among salvage treatment modalities difficult. Triggers for intervention and factors predicting response to salvage therapy vary. Conclusions Radiation therapy (RT) after RP can provide durable prostate-specific antigen (PSA) responses in a sizeable percentage of men, especially when given early (ie, PSA <1 ng/ml). Though a few studies suggest improvements in mortality, prospective randomized trials are needed and underway. The role of salvage treatment after RT is less clear.

Original languageEnglish (US)
Pages (from-to)905-915
Number of pages11
JournalEuropean Urology
Volume64
Issue number6
DOIs
StatePublished - Dec 2013
Externally publishedYes

Fingerprint

Salvage Therapy
Prostatic Neoplasms
Recurrence
Prostatectomy
Prostate-Specific Antigen
Radiotherapy
Therapeutics
Radiation
Cryosurgery
Cryotherapy
Brachytherapy
Disease Management
Publications
Meta-Analysis
Guidelines
Mortality
Neoplasms

Keywords

  • Management
  • Prostate cancer
  • Recurrence

ASJC Scopus subject areas

  • Urology

Cite this

Punnen, S., Cooperberg, M. R., D'Amico, A. V., Karakiewicz, P. I., Moul, J. W., Scher, H. I., ... Freedland, S. J. (2013). Management of biochemical recurrence after primary treatment of prostate cancer: A systematic review of the literature. European Urology, 64(6), 905-915. https://doi.org/10.1016/j.eururo.2013.05.025

Management of biochemical recurrence after primary treatment of prostate cancer : A systematic review of the literature. / Punnen, Sanoj; Cooperberg, Matthew R.; D'Amico, Anthony V.; Karakiewicz, Pierre I.; Moul, Judd W.; Scher, Howard I.; Schlomm, Thorsten; Freedland, Stephen J.

In: European Urology, Vol. 64, No. 6, 12.2013, p. 905-915.

Research output: Contribution to journalArticle

Punnen, S, Cooperberg, MR, D'Amico, AV, Karakiewicz, PI, Moul, JW, Scher, HI, Schlomm, T & Freedland, SJ 2013, 'Management of biochemical recurrence after primary treatment of prostate cancer: A systematic review of the literature', European Urology, vol. 64, no. 6, pp. 905-915. https://doi.org/10.1016/j.eururo.2013.05.025
Punnen, Sanoj ; Cooperberg, Matthew R. ; D'Amico, Anthony V. ; Karakiewicz, Pierre I. ; Moul, Judd W. ; Scher, Howard I. ; Schlomm, Thorsten ; Freedland, Stephen J. / Management of biochemical recurrence after primary treatment of prostate cancer : A systematic review of the literature. In: European Urology. 2013 ; Vol. 64, No. 6. pp. 905-915.
@article{d711100b79d04cd1b8d894acb688b323,
title = "Management of biochemical recurrence after primary treatment of prostate cancer: A systematic review of the literature",
abstract = "Context Despite excellent cancer control with the treatment of localized prostate cancer (PCa), some men will experience a recurrence of disease. The optimal management of recurrent disease remains uncertain. Objective To systematically review recent literature regarding management of biochemical recurrence after primary treatment for localized PCa. Evidence acquisition A comprehensive systematic review of the literature was performed from 2000 to 2012 to identify articles pertaining to management after recurrent PCa. Search terms included prostate cancer recurrence, salvage therapy, radiorecurrent prostate cancer, post HIFU, post cryoablation, postradiation, and postprostatectomy salvage. Studies were selected according to Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines and required to provide a comprehensive description of primary and secondary treatments along with outcomes. Evidence synthesis The data from 32 original publications were reviewed. The most common option for local salvage therapy after radical prostatectomy (RP) was radiation. Options for local salvage therapy after primary radiation included RP, brachytherapy, and cryotherapy. Different definitions of recurrence and risk profiles among patients make comparative assessment among salvage treatment modalities difficult. Triggers for intervention and factors predicting response to salvage therapy vary. Conclusions Radiation therapy (RT) after RP can provide durable prostate-specific antigen (PSA) responses in a sizeable percentage of men, especially when given early (ie, PSA <1 ng/ml). Though a few studies suggest improvements in mortality, prospective randomized trials are needed and underway. The role of salvage treatment after RT is less clear.",
keywords = "Management, Prostate cancer, Recurrence",
author = "Sanoj Punnen and Cooperberg, {Matthew R.} and D'Amico, {Anthony V.} and Karakiewicz, {Pierre I.} and Moul, {Judd W.} and Scher, {Howard I.} and Thorsten Schlomm and Freedland, {Stephen J.}",
year = "2013",
month = "12",
doi = "10.1016/j.eururo.2013.05.025",
language = "English (US)",
volume = "64",
pages = "905--915",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Management of biochemical recurrence after primary treatment of prostate cancer

T2 - A systematic review of the literature

AU - Punnen, Sanoj

AU - Cooperberg, Matthew R.

AU - D'Amico, Anthony V.

AU - Karakiewicz, Pierre I.

AU - Moul, Judd W.

AU - Scher, Howard I.

AU - Schlomm, Thorsten

AU - Freedland, Stephen J.

PY - 2013/12

Y1 - 2013/12

N2 - Context Despite excellent cancer control with the treatment of localized prostate cancer (PCa), some men will experience a recurrence of disease. The optimal management of recurrent disease remains uncertain. Objective To systematically review recent literature regarding management of biochemical recurrence after primary treatment for localized PCa. Evidence acquisition A comprehensive systematic review of the literature was performed from 2000 to 2012 to identify articles pertaining to management after recurrent PCa. Search terms included prostate cancer recurrence, salvage therapy, radiorecurrent prostate cancer, post HIFU, post cryoablation, postradiation, and postprostatectomy salvage. Studies were selected according to Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines and required to provide a comprehensive description of primary and secondary treatments along with outcomes. Evidence synthesis The data from 32 original publications were reviewed. The most common option for local salvage therapy after radical prostatectomy (RP) was radiation. Options for local salvage therapy after primary radiation included RP, brachytherapy, and cryotherapy. Different definitions of recurrence and risk profiles among patients make comparative assessment among salvage treatment modalities difficult. Triggers for intervention and factors predicting response to salvage therapy vary. Conclusions Radiation therapy (RT) after RP can provide durable prostate-specific antigen (PSA) responses in a sizeable percentage of men, especially when given early (ie, PSA <1 ng/ml). Though a few studies suggest improvements in mortality, prospective randomized trials are needed and underway. The role of salvage treatment after RT is less clear.

AB - Context Despite excellent cancer control with the treatment of localized prostate cancer (PCa), some men will experience a recurrence of disease. The optimal management of recurrent disease remains uncertain. Objective To systematically review recent literature regarding management of biochemical recurrence after primary treatment for localized PCa. Evidence acquisition A comprehensive systematic review of the literature was performed from 2000 to 2012 to identify articles pertaining to management after recurrent PCa. Search terms included prostate cancer recurrence, salvage therapy, radiorecurrent prostate cancer, post HIFU, post cryoablation, postradiation, and postprostatectomy salvage. Studies were selected according to Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines and required to provide a comprehensive description of primary and secondary treatments along with outcomes. Evidence synthesis The data from 32 original publications were reviewed. The most common option for local salvage therapy after radical prostatectomy (RP) was radiation. Options for local salvage therapy after primary radiation included RP, brachytherapy, and cryotherapy. Different definitions of recurrence and risk profiles among patients make comparative assessment among salvage treatment modalities difficult. Triggers for intervention and factors predicting response to salvage therapy vary. Conclusions Radiation therapy (RT) after RP can provide durable prostate-specific antigen (PSA) responses in a sizeable percentage of men, especially when given early (ie, PSA <1 ng/ml). Though a few studies suggest improvements in mortality, prospective randomized trials are needed and underway. The role of salvage treatment after RT is less clear.

KW - Management

KW - Prostate cancer

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=84887402225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887402225&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2013.05.025

DO - 10.1016/j.eururo.2013.05.025

M3 - Article

C2 - 23721958

AN - SCOPUS:84887402225

VL - 64

SP - 905

EP - 915

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 6

ER -